Endospan says Artivion has closed its acquisition after FDA approved the NEXUS aortic arch system

Artivion said it has completed its acquisition of Endospan, closing the deal after the U.S. Food and Drug Administration approved Endospan’s NEXUS aortic arch system in April.

The company said the transaction closed on May 18, 2026. Artivion said it funded the $135 million upfront net purchase price with a previously drawn $150 million delayed-draw term loan.

Endospan had been the developer of the NEXUS aortic arch stent graft system. The FDA granted premarket approval for the device on April 2, 2026, with the agency’s notice dated April 7, 2026.

Artivion said it had been the exclusive distributor of NEXUS in EMEA since 2019, giving the company an existing commercial link to the product before the acquisition closed.

The deal gives Artivion direct control of a newly approved device as it moves toward commercialization. No additional integration or revenue guidance was announced with the closing.

What happens next

Artivion will likely focus on integrating Endospan and advancing NEXUS commercialization following the close. Further details could emerge in future filings or company updates.